Passive Immunity Trial of Nashville II for COVID-19 (PassItOnII)

Clinical Trial ID NCT04362176

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04362176

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012 21.04
2 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020 10.90
3 Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020 9.53
4 A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020 7.78
5 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 6.59
6 The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clin Infect Dis 2015 3.83
7 Sample size calculations for ordered categorical data. Stat Med 1993 3.15
8 Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004 2.64
9 Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007 2.53
10 Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995 1.86
11 Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011 1.68
12 Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 2004 1.30
13 Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol 2014 1.28
14 Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005 1.23
15 Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 2001 1.11
16 Passive antibody therapies: progress and continuing challenges. Clin Immunol 1999 1.09
17 Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005 1.03
18 Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol 2016 0.96
19 Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus 2015 0.96
20 Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis 2016 0.94
21 Cognitively impaired subjects. American College of Physicians. Ann Intern Med 1989 0.84
22 A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol 2005 0.81
23 Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect 2016 0.76
24 Another Decade, Another Coronavirus. N Engl J Med 2020 0.75
25 Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis 2015 0.75
26 Covid-19 - The Search for Effective Therapy. N Engl J Med 2020 0.75
Next 100